enVista MX60 IOL
Device
Bausch & Lomb Americas Inc.
Total Payments
$5.4M
Transactions
7,229
Doctors
3,076
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $380,951 | 2,023 | 1,252 |
| 2023 | $1.2M | 2,248 | 1,357 |
| 2022 | $1.9M | 1,781 | 967 |
| 2021 | $2.0M | 1,177 | 675 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.8M | 406 | 88.0% |
| Food and Beverage | $312,717 | 6,713 | 5.8% |
| Consulting Fee | $169,566 | 38 | 3.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $119,152 | 25 | 2.2% |
| Compensation for serving as faculty or as a speaker for a medical education program | $34,683 | 16 | 0.6% |
| Travel and Lodging | $10,439 | 30 | 0.2% |
| Space rental or facility fees (teaching hospital only) | $1,250 | 1 | 0.0% |
Payments by Type
Research
$4.8M
406 transactions
General
$647,808
6,823 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PROSPECTIVE, MULTICENTER, RANDOMIZED, ACTIVE-CONTROLLED CLINICAL STUDY TO EVALUATE THE SAFETY AND EFFECTIVENESS OF THE ENVISTA ONE-PIECE HYDROPHOBIC ACRYLIC TRIFOCAL INTRAOCULAR LENS IN SUBJECTS UNDERGOING CATARACT EXTRACTION | Bausch Health US, LLC | $1.9M | 3 |
| A PROSPECTIVE, MULTICENTER, RANDOMIZED, ACTIVE-CONTROLLED CLINICAL STUDY TO EVALUATE THE SAFETY AND EFFECTIVENESS OF THE ENVISTA ONE-PIECE HYDROPHOBIC ACRYLIC TRIFOCAL INTRAOCULAR LENS IN SUBJECTS UNDERGOING CATARACT EXTRACTION | Bausch & Lomb Americas Inc. | $1.4M | 1 |
| A PROSPECTIVE, MULTICENTER, RANDOMIZED, ACTIVE-CONTROLLED CLINICAL STUDY TO EVALUATE THE SAFETY AND EFFECTIVENESS OF THE ENVISTA ONE-PIECE HYDROPHOBIC ACRYLIC TRIFOCAL INTRAOCULAR LENS IN SUBJECTS UNDERGOING CATARACT EXTRACTION | Bausch & Lomb Americas Inc. | $976,671 | 1 |
| A PROSPECTIVE, MULTICENTER, RANDOMIZED, MASKED, ACTIVE CONTROLLED CLINICAL STUDY TO EVALUATE THE SAFETY AND EFFECTIVENESS OF THE ENVISTA ONE-PIECE HYDROPHOBIC ACRYLIC TRIFOCAL INTRAOCULAR LENS IN SUBJECTS UNDERGOING CATARACT EXTRACTION. | Bausch & Lomb Americas Inc. | $132,300 | 0 |
| A PROSPECTIVE, MULTICENTER, POST MARKET OBSERVATIONAL STUDY TO EVALUATE ROTATIONAL STABILITY AND FUNCTIONAL VISUAL ACUITY OF THE ENVISTA ONE-PIECE HYDROPHOBIC ACRYLIC TORIC IOL MX60ET FOLLOWING CATARACT SURGERY | Bausch Health US, LLC | $111,443 | 0 |
| A Prospective, Single-Center, Randomized Clinical Investigation to Evaluate the Performance of enVista Aspire (EA) Intraocular Lens against a Control and an Active-Comparator in Subjects Undergoing Cataract Extraction and Implantation of an Intraocular Lens | Bausch & Lomb Americas Inc. | $78,072 | 2 |
| A PROSPECTIVE, MULTICENTER, RANDOMIZED, MASKED, ACTIVE CONTROLLED CLINICAL STUDY TO EVALUATE THE SAFETY AND EFFECTIVENESS OF THE ENVISTA ONE-PIECE HYDROPHOBIC ACRYLIC TRIFOCAL INTRAOCULAR LENS IN SUBJECTS UNDERGOING CATARACT EXTRACTION. | Bausch Health US, LLC | $57,300 | 0 |
| A Non-interventional, Prospective, Multicenter, Single Arm, Post-Marketing Clinical Study to Evaluate the enVista Aspire (EA) Intraocular Lens in Subjects Undergoing Cataract Extraction | Bausch & Lomb Americas Inc. | $57,122 | 0 |
| A PROSPECTIVE, MULTICENTER, POST MARKET OBSERVATIONAL STUDY TO EVALUATE ROTATIONAL STABILITY AND FUNCTIONAL VISUAL ACUITY OF THE ENVISTA ONE-PIECE HYDROPHOBIC ACRYLIC TORIC IOL MX60ET FOLLOWING CATARACT SURGERY | Bausch & Lomb Americas Inc. | $22,313 | 0 |
| Correction of mild astigmatism in cataract surgery using low diopter monofocal toric IOL compared to non-toric spherical control: A Retrospective Study | Bausch Health US, LLC | $15,000 | 1 |
| Correction of mild astigmatism in cataract surgery using low diopter monofocal toric IOL compared to non-toric spherical control; a Retrospective Study | Bausch & Lomb Americas Inc. | $14,000 | 1 |
Top Doctors Receiving Payments for enVista MX60 IOL
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Las Vegas, NV | $4.4M | 382 |
| , MD | Ophthalmology | Saint Louis, MO | $185,886 | 25 |
| , M.D | Ophthalmology | Northridge, CA | $145,581 | 33 |
| , MD | Ophthalmology | Springfield, IL | $76,072 | 5 |
| , MD | Ophthalmology | Nashville, TN | $51,275 | 9 |
| , M.D., P.A | Ophthalmology | Venice, FL | $37,437 | 9 |
| , O.D | Optometrist | Lake Forest, CA | $28,200 | 2 |
| , MD | Ophthalmology | Cincinnati, OH | $20,700 | 1 |
| , MD | Ophthalmology | Lebanon, KY | $18,103 | 5 |
| , M.D | Ophthalmology | Woodland Park, NJ | $16,740 | 54 |
| , M.D., PH.D | Specialist | Bel Air, MD | $15,478 | 9 |
| , M.D | Ophthalmology | New York, NY | $14,002 | 9 |
| , M.D | Ophthalmology | Long Branch, NJ | $12,167 | 22 |
| , MD | Ophthalmology | Las Vegas, NV | $11,809 | 9 |
| , MD | Ophthalmology | Valhalla, NY | $10,653 | 26 |
| , MD | Ophthalmology | New Haven, CT | $9,638 | 57 |
| , D.O | Ophthalmology | Crossville, TN | $7,571 | 20 |
| , M.D | Ophthalmology | Columbus, OH | $6,563 | 3 |
| , M.D | Ophthalmology | Rutherford, NJ | $6,279 | 9 |
| , M.D | Ophthalmology | Birmingham, MI | $4,439 | 2 |
| , M.D | Ophthalmology | Newport Beach, CA | $4,438 | 4 |
| , M.D | Ophthalmology | Brecksville, OH | $4,350 | 1 |
| , MD | Ophthalmology | Dover, NJ | $4,342 | 53 |
| , MD | Ophthalmology | Miami, FL | $4,004 | 6 |
| , M.D | Ophthalmology | Freehold, NJ | $3,757 | 12 |
Ad
Manufacturing Companies
Product Information
- Type Device
- Total Payments $5.4M
- Total Doctors 3,076
- Transactions 7,229
About enVista MX60 IOL
enVista MX60 IOL is a device associated with $5.4M in payments to 3,076 healthcare providers, recorded across 7,229 transactions in the CMS Open Payments database. The primary manufacturer is Bausch & Lomb Americas Inc..
Payment data is available from 2021 to 2024. In 2024, $380,951 was paid across 2,023 transactions to 1,252 doctors.
The most common payment nature for enVista MX60 IOL is "Unspecified" ($4.8M, 88.0% of total).
enVista MX60 IOL is associated with 11 research studies, including "A PROSPECTIVE, MULTICENTER, RANDOMIZED, ACTIVE-CONTROLLED CLINICAL STUDY TO EVALUATE THE SAFETY AND EFFECTIVENESS OF THE ENVISTA ONE-PIECE HYDROPHOBIC ACRYLIC TRIFOCAL INTRAOCULAR LENS IN SUBJECTS UNDERGOING CATARACT EXTRACTION" ($1.9M).